|Chennai||Rs. 24840.00 (-0.36%)|
|Mumbai||Rs. 25460.00 (-0.16%)|
|Delhi||Rs. 25450.00 (2.21%)|
|Kolkata||Rs. 25000.00 (0%)|
|Kerala||Rs. 24700.00 (0%)|
|Bangalore||Rs. 25050.00 (1.42%)|
|Hyderabad||Rs. 24930.00 (1.63%)|
The Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine has announced that the University of California San Diego Moores Cancer Center has joined as a member of the Consortium. WIN is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.
UCSD Moores is NCI-designated as a Comprehensive Cancer Center, a ranking conferred on select institutions that stand at the forefront of NCI-supported cancer research. With a faculty that includes Nobel Laureates and members of the National Academy of Sciences, advanced competencies in biobanking, and a new Center for Advanced Laboratory Medicine equipped to conduct the most advanced genome-wide sequencing techniques, the UCSD Moores Cancer Center will play an integral role in developing and implementing innovative, worldwide WIN clinical trials and projects based on the latest discoveries in personalized cancer research.
“We are thrilled that UCSD Moores Cancer Center has become a member of WIN,” stated Dr. John Mendelsohn, WIN Consortium Chairman. “UCSD’s outstanding faculty are strongly engaged in collaborative efforts to advance personalized cancer medicine. With its advanced technical capabilities and talented, motivated scientists, the Moores Cancer Center significantly enhances WIN’s ability to bring the latest advances in personalized cancer medicine to patients.”
According to Dr. Scott Lippman, Director of the UCSD Moores Cancer Center, “this linkage with WIN enables UCSD to propose and participate in ground-breaking, global clinical trials with leading organizations striving to advance personalized cancer medicine. This type of cross-sector collaboration is an important step if we are to quickly bring the benefits of genome-driven discoveries to patients.”
Initiated in 2010 by the University of Texas MD Anderson Cancer Center (USA) and the Institut Gustave Roussy (France), the WIN Consortium is a global network of 29 leading organizations from the academic, pharmaceutical, biotechnology, healthcare IT, and patient advocacy sectors working to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN is a non-governmental, not-for-profit organization headquartered in Paris.
For further information, please visit www.winconsortium.org.